Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback